Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus

Completed · Phase 4

Conditions studied: Hypertension

In brief

This study evaluated the efficacy and safety of amlodipine/benazepril compared with that of enalapril in the treatment of hypertension in African-American patients with type 2 diabetes.

Key facts

Study ID

NCT00367978

Run by

Novartis

People needed

275

Starts

2001-12-01

Expected to finish

2003-09-01

Last updated by the study team

2011-11-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• African-American
• males and females
• current diagnosis of type 2 diabetes documented by medical history;
• mean sitting diastolic blood pressure of ≥ 90 and ≤ 110 mm Hg;
• HbA1C ≤ 9.5%

You may not qualify if…

• having unilateral or bilateral renal artery stenosis;
• having clinically significant cardiac dysrhythmias;
• having a significant history of coronary artery disease within the past 6 months;
• having a history or diagnosis of congestive heart failure (CHF);
• having any clinically relevant cardiac valvular disease

Where it is running

• Novartis Pharmaceuticals Corporation — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.